Ethris has joined forces with Lonza to develop room-temperature stable, spray-dried mRNA-based vaccine formulations.

Ethris与Lonza合作，开发室温稳定的喷雾干燥mRNA疫苗配方。

These vaccines are intended for mucosal delivery and could offer a new approach to preventing respiratory illnesses.

这些疫苗旨在通过黏膜递送，可能为预防呼吸道疾病提供一种新方法。

The collaboration targets one of the key challenges facing current mRNA vaccines – their reliance on ultra-low temperature storage and complex delivery systems. By developing formulations that remain stable at room temperature, the partnership aims to streamline the supply chain, lower production costs, and enable faster and more scalable vaccine deployment..

该合作针对当前mRNA疫苗面临的其中一个关键挑战——它们依赖于超低温储存和复杂的递送系统。通过开发在室温下仍能保持稳定的配方，这一合作伙伴关系旨在简化供应链、降低生产成本，并实现更快速且更大规模的疫苗部署。

In addition, the needle-free, nasal delivery method being developed may trigger mucosal immunity, offering protection directly at the virus’s entry point.

此外，正在开发的无针鼻腔递送方法可能会触发粘膜免疫，直接在病毒进入点提供保护。

Initially, the two companies will work on a nasal mRNA vaccine candidate for influenza. The goal is to produce a non-invasive vaccine that can offer localised immune responses similar to those seen with injectable vaccines.

最初，两家公司将合作开发一款流感的鼻腔mRNA疫苗候选产品。目标是生产一种非侵入性疫苗，能够提供类似于注射疫苗的局部免疫反应。

This method could also play a role in reducing transmission rates by generating immunity in the upper respiratory tract.

这种方法还可能通过在上呼吸道产生免疫力来降低传播率。

Lonza will be responsible for the spray-drying and particle engineering processes. This will be carried out at its Bend site in the United States, which specialises in improving drug bioavailability and pharmacokinetics.

龙沙将负责喷雾干燥和颗粒工程工艺。这项工作将在其位于美国的本德工厂进行，该工厂专注于改善药物的生物利用度和药代动力学。

The work will involve Ethris’ proprietary SNIM® RNA (stabilised non-immunogenic mRNA) and SNaP LNP (stabilised lipid nanoparticles) platforms. These technologies are designed to maintain mRNA stability and activity, ensuring effective delivery to the respiratory tract.

这项工作将涉及 Ethris 专有的 SNIM® RNA（稳定的非免疫原性 mRNA）和 SNaP LNP（稳定的脂质纳米颗粒）平台。这些技术旨在保持 mRNA 的稳定性和活性，确保有效递送到呼吸道。

The collaboration is also supported by a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) and combines Lonza’s manufacturing capabilities with Ethris’ innovative RNA platform.

该合作还得到了流行病防范创新联盟（CEPI）的资助，结合了龙沙的生产能力与Ethris的创新RNA平台。

Together, they aim to address unmet medical needs in the area of respiratory disease prevention through non-invasive vaccine delivery.

他们共同致力于通过非侵入性疫苗递送方式，满足在呼吸道疾病预防领域的未满足医疗需求。

Source: lonza.com

来源：lonza.com